Medpace Holdings, Inc. filings document formal disclosures for a global clinical contract research organization, including 8-K reports that furnish quarterly and annual financial results. Those reports cover operating measures such as revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios for its Phase I-IV clinical development services.
Medpace filings also include proxy materials addressing governance, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document credit-facility amendments involving operating subsidiaries and executive-officer succession matters.
At Medpace Holdings, Inc., General Counsel & Corp. Secy. Stephen P. Ewald sold 1,245 shares of common stock at $690 per share on October 29, 2026. The sale was effected pursuant to a limit order placed during an open window period. Ewald directly held 19,098 shares afterward; no Rule 10b5-1 plan is reported.
Medpace Holdings, Inc. (MEDP) officer Stephen P. Ewald reported a proposed sale of 1,245 common shares, with an aggregate market value of $859,050.00 and an approximate sale date of October 29, 2026. Fidelity Brokerage Services LLC is named as broker. The shares were acquired from the issuer through a stock option exercise on October 27, 2025. Wade Moss signed as a duly authorized representative of Fidelity Brokerage Services LLC and attorney-in-fact for Ewald.
Susan E. Burwig, Medpace Holdings, Inc.’s Executive Vice President, Operations, exercised options for 328 common shares at $166.73 per share on October 26, 2026. She sold 16,060 common shares that day and 3,940 on October 27, 2026, at $677 per share. The sales were effected pursuant to a limit order she placed during an open window period; no Rule 10b5-1 plan is reported.
Medpace Holdings, Inc. officer Susan Burwig reported a proposed sale of 3,940 common shares, with an aggregate market value of $2,667,380 and an approximate sale date of October 27, 2026. Fidelity Brokerage Services LLC is listed as broker, and NASDAQ as the exchange.
The shares are listed as acquired from the issuer through a stock option exercise on September 26, 2025, for cash. Burwig’s reported sales during the preceding three months included 7,500 shares on July 28, 2026, and 16,060 shares on October 26, 2026.
Medpace Holdings, Inc. officer Susan E. Burwig reported a proposed sale of 16,060 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $10,872,620.00 and an approximate sale date of October 26, 2026. The notice lists a prior sale by Susan Burwig of 7,500 common shares for $4,500,000.00 on July 28, 2026, and stock-option exercises for cash involving 10,000 shares on August 26, 2025, and 6,060 shares on September 26, 2025. Jennifer Ruchti signed as a duly authorized representative of Fidelity Brokerage Services LLC and attorney-in-fact for Susan E. Burwig.
Medpace Holdings, Inc. executive vice president of operations Susan E. Burwig exercised options for 2,700 shares of common stock on October 21, 2026, at an exercise price of $166.73 per share. The option had vested in full on October 27, 2025. After the transaction, her reported direct holdings were 73,684 common shares and 328 employee stock options.
Medpace Holdings, Inc. reported third-quarter revenue of $716.0 million, up 8.5% from $659.9 million a year earlier. Net income was $137.5 million versus $111.1 million, and diluted earnings per share were $4.84 versus $3.86.
For the nine months ended September 30, 2026, revenue was $2,129.9 million, up 16.9%, and net income was $382.7 million versus $316.0 million. Net cash provided by operating activities was $530.4 million; cash and cash equivalents were $705.3 million as of September 30, 2026. Medpace repurchased 705,616 shares for $294.7 million during the nine months and made no repurchases in the third quarter. Effective October 20, 2026, its board approved a new authorization of up to $1.0 billion after terminating the current authorization.
Separately, August J. Troendle, chief executive officer, president and chairman of the board, adopted a Rule 10b5-1 plan to sell up to 307,959 shares. Susan E. Burwig, executive vice president, operations, adopted one for up to 7,500 shares, and Kevin M. Brady, chief financial officer and treasurer, one for up to 3,400 shares.
Medpace Holdings, Inc. (MEDP) reported third-quarter 2026 revenue of $716.0 million, up 8.5% year over year. GAAP net income was $137.5 million, or $4.84 per diluted share, versus $111.1 million and $3.86; EBITDA was $172.1 million, up 16.0%. Backlog was $3,167.2 million as of September 30, 2026, up 5.6% year over year. Nine-month GAAP net income was $382.7 million.
Medpace forecast 2026 revenue of $2.835 billion to $2.855 billion, GAAP net income of $514.0 million to $524.0 million, EBITDA of $638.0 million to $652.0 million, and diluted GAAP EPS of $17.97 to $18.32. Effective October 20, 2026, the board ended the authorization with $527.0 million remaining and approved a new authorization for up to $1.0 billion in common-stock repurchases until December 31, 2028, at management’s discretion. Repurchases will be funded from cash on hand and may use open-market, privately negotiated, Rule 10b5-1 or other transactions. The authorization requires no minimum purchases and may be modified, limited, extended, suspended or terminated by the board at any time without prior notice.
Medpace Holdings, Inc. Executive Vice President, Operations Susan E. Burwig exercised options for 3,000 common shares on October 12, 2026, at an exercise price of $166.73 per share. Afterward, she reported holding 70,984 common shares and 3,028 options. The transaction was not reported under a Rule 10b5-1 plan.
At Medpace Holdings, Inc., Executive Vice President of Operations Susan E. Burwig exercised options for 2,000 common shares on October 7, 2026, at an exercise price of $166.73 per share. The report records 2,000 options disposed and 2,000 common shares acquired in the exercise. Afterward, her reported direct holdings were 67,984 common shares and 6,028 options.